Adaptimmune Therapeutics Total Assets 2015-2021 | ADAP

Adaptimmune Therapeutics total assets from 2015 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Adaptimmune Therapeutics Annual Total Assets
(Millions of US $)
2020 $451
2019 $182
2018 $277
2017 $281
2016 $235
2015 $301
2014 $53
2013 $53
Adaptimmune Therapeutics Quarterly Total Assets
(Millions of US $)
2021-09-30 $354
2021-06-30 $390
2021-03-31 $412
2020-12-31 $451
2020-09-30 $479
2020-06-30 $512
2020-03-31 $285
2019-12-31 $182
2019-09-30 $208
2019-06-30 $240
2019-03-31 $270
2018-12-31 $277
2018-09-30 $310
2018-06-30 $211
2018-03-31 $247
2017-12-31 $281
2017-09-30 $301
2017-06-30 $284
2017-03-31 $266
2016-12-31 $235
2016-09-30 $223
2016-06-30 $240
2016-03-31 $262
2015-09-30 $304
2015-06-30 $301
2015-03-31 $0
2014-12-31 $140
2014-06-30 $53
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.478B $0.004B
Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75